Rep. Maria Elvira Salazar Purchases Shares of Biogen Inc. (NASDAQ:BIIB)

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $50,001 and $100,000 in Biogen stock on May 11th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
• Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
• Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $1,001 – $15,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $15,001 – $50,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Purchased $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Sold $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 5/12/2026.
• Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/12/2026.
• Sold $1,001 – $15,000 in shares of Whirlpool (NYSE:WHR) on 5/11/2026.
• Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/11/2026.

Biogen Price Performance

Shares of BIIB opened at $194.24 on Thursday. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97. The stock has a market cap of $28.68 billion, a PE ratio of 20.84 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The firm has a fifty day moving average price of $188.07 and a 200 day moving average price of $184.03.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the previous year, the company earned $3.02 earnings per share. Biogen’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, sell-side analysts anticipate that Biogen Inc. will post 14.18 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Royal Bank Of Canada upped their target price on shares of Biogen from $222.00 to $227.00 and gave the company an “outperform” rating in a report on Wednesday, May 27th. Sanford C. Bernstein dropped their price target on shares of Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. Citigroup upped their target price on shares of Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Needham & Company LLC raised shares of Biogen from a “hold” rating to a “buy” rating and set a $255.00 target price for the company in a report on Monday. Finally, Wedbush increased their price target on shares of Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and an average target price of $217.26.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Needham upgraded Biogen to Buy and set a $255 price target, citing a stronger outlook for the commercial portfolio and multiple Phase 3 readouts through 2029, including potential upside from Leqembi and recently acquired products. Article Title
• Positive Sentiment: At Biogen’s 2026 annual meeting, shareholders backed the board, auditor, and pay policies, which suggests governance support and no major shareholder revolt. Article Title
• Neutral Sentiment: Commentary comparing Biogen with other biotech stocks says the company has recently outperformed peers and analysts remain reasonably upbeat, reinforcing a stable sentiment backdrop rather than a new catalyst. Article Title
• Negative Sentiment: The Schall Law Firm announced a securities-law investigation into whether Biogen made false or misleading statements or omitted material information, adding headline risk and potential litigation overhang. Article Title
• Negative Sentiment: Pomerantz LLP also launched an investor investigation into Biogen, reinforcing concerns that the stock could face legal scrutiny and additional uncertainty. Article Title

Institutional Trading of Biogen

Institutional investors and hedge funds have recently made changes to their positions in the company. Reflection Asset Management acquired a new stake in shares of Biogen during the 4th quarter worth $25,000. WPG Advisers LLC increased its holdings in shares of Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after buying an additional 117 shares during the last quarter. First Horizon Corp acquired a new stake in shares of Biogen during the 4th quarter worth $30,000. Root Financial Partners LLC lifted its holdings in shares of Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 123 shares in the last quarter. Finally, MV Capital Management Inc. acquired a new position in shares of Biogen during the 4th quarter valued at $34,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.